Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
| العنوان: | Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy |
|---|---|
| المؤلفون: | Jared Lunceford, Michael Nebozhyn, Chunsheng Zhang, Joanne E. Tomassini, Elizabeth R. Plimack, Erin Murphy, Andrea L. Webber, Xinwei Sher, Razvan Cristescu, Robin Mogg, Patrick A. Ott, David Ross Kaufman, Andrew Albright, Xiaoqiao Liu, Jennifer H. Yearley, Terrill K. McClanahan, Andrey Loboda, Mark Ayers, Antoni Ribas, Tanguy Y. Seiwert, Nageatte Ibrahim, Jonathan D. Cheng, Andrew K. Joe, Hongchao Lu |
| المصدر: | Science (New York, N.Y.), vol 362, iss 6411 Cristescu, R; Mogg, R; Ayers, M; Albright, A; Murphy, E; Yearley, J; et al.(2018). Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. SCIENCE, 362(6411), 197-+. doi: 10.1126/science.aar3593. UCLA: Retrieved from: http://www.escholarship.org/uc/item/9qc224gk |
| بيانات النشر: | eScholarship, University of California, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | 0301 basic medicine, Cell cycle checkpoint, medicine.medical_treatment, T-Lymphocytes, Programmed Cell Death 1 Receptor, Pembrolizumab, 0302 clinical medicine, Antineoplastic Agents, Immunological, Neoplasms, Monoclonal, Molecular Targeted Therapy, Humanized, Cancer, Multidisciplinary, Tumor, Tumor Burden, medicine.anatomical_structure, Immunological, 030220 oncology & carcinogenesis, Immunotherapy, 4.2 Evaluation of markers and technologies, Genetic Markers, General Science & Technology, T cell, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Antibodies, Vaccine Related, 03 medical and health sciences, medicine, Biomarkers, Tumor, Genetics, Humans, Inflammation, business.industry, Human Genome, Cell Cycle Checkpoints, Blockade, 4.1 Discovery and preclinical testing of markers and technologies, Clinical trial, 030104 developmental biology, Mutation, Cancer research, Immunization, business, Transcriptome, Checkpoint Blockade Immunotherapy, Biomarkers |
| الوصف: | Mining immunotherapy clinical trials Clinical trial data can provide a wealth of information about how drugs work. Yet such information often belongs to pharmaceutical companies and is rarely accessible to the scientific community at large. Cristescu et al. provide exploratory analysis of a cancer genomics dataset, collected from four separate clinical trials of Merck's PD-1 immunotherapy drug, pembrolizumab. This informative public resource examines more than 300 patient samples representing 22 different tumor types. Two widely used signatures that currently predict immunotherapy response are tumor mutational burden and a “hot” T cell–inflamed microenvironment. The study analyzed these two proposed biomarkers in combination to see what predictive clinical utility they may hold. Science , this issue p. eaar3593 |
| وصف الملف: | application/pdf |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73c7282e36ccb9bee388d9f39ca9451f https://escholarship.org/uc/item/9qc224gk |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....73c7282e36ccb9bee388d9f39ca9451f |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |